Prätherapeutische Biomarker des Lungenkarzinoms unter besonderer Berücksichtigung der Bronchoskopie

Zusammenfassung

Molekulare Biomarker bekommen eine zunehmende Bedeutung in der Behandlung von Patienten mit einem Lungenkarzinom. Sie unterstützen die Diagnosestellung, die Wahl der Therapie und helfen bei der Einschätzung der Prognose. Aktuell ist die bronchoskopische Probenentnahme mit der Bestimmung Gewebe-basierter Marker das Verfahren der Wahl. Möglicherweise wird sich dies zukünftig ändern, wenn nichtinvasive Methoden zur Markerbestimmung aus Blut oder Ausatemluft etabliert werden können. Bis dahin ist insbesondere von Bedeutung, mit welcher Methodik die Proben entnommen werden und wie sie prozessiert werden auf dem Weg in das pathologische Labor.

Abstract

Molecular biomarkers are becoming increasingly significant in the workup of lung carcinoma patients. They assist in diagnosis, selecting the most adequate therapy and determining prognosis. Obtaining blood based biomarkers or volatile markers in exhaled breath may provide a less invasive method in the future. For the time being, bronchoscopy is still the method of choice to obtain specimen and assess tissue based biomarkers. The techniques how specimen are collected and processed for analysis are of paramount importance.

• Literatur

• 1 Aberle DR et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395-409
• 2 Horeweg N et al. Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial. Am J Respir Crit Care Med 2013; 187: 848-854
• 3 Patz Jr EF et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med 2014; 174: 269-274
• 4 Hensing TA, Salgia R. Molecular biomarkers for future screening of lung cancer. J Surg Oncol 2013; 108: 327-333
• 5 Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005; 5: 845-856
• 6 Miekisch W, Herbig J, Schubert JK. Data interpretation in breath biomarker research: pitfalls and directions. J Breath Res 2012; 6: 036007
• 7 Kinsey CM, Arenberg DA. EBUS-TBNA for Non-Small Cell Lung Cancer Staging. Am J Respir Crit Care Med 2014; [Epub ahead of print]
• 8 Lee HS, Lee GK, Lee HS et al. Real-time endobronchial ultrasound-guided transbronchial needle aspiration in mediastinal staging of non-small cell lung cancer: how many aspirations per target lymph node station?. Chest 2008; 134: 368-374
• 9 Nakajima T et al. Treatment of lung cancer with an ALK inhibitor after EML4-ALK fusion gene detection using endobronchial ultrasound-guided transbronchial needle aspiration. J Thorac Oncol 2010; 5: 2041-2043
• 10 Nakajima T et al. Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration. Chest 2007; 132: 597-602
• 11 Lim EH et al. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J Thorac Oncol 2009; 4: 12-21
• 12 Awad MM et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 2013; 368: 2395-2401
• 13 Hetzel J, Eberhardt R, Herth FJ et al. Cryobiopsy increases the diagnostic yield of endobronchial biopsy: a multicentre trial. The European respiratory journal 2012; 39: 685-690
• 14 Gex G, Pralong JA, Combescure C et al. Diagnostic Yield and Safety of Electromagnetic Navigation Bronchoscopy for Lung Nodules: A Systematic Review and Meta-Analysis. Respiration 2014; 87: 165-176
• 15 Steinfort DP, Khor YH, Manser RL et al. Radial probe endobronchial ultrasound for the diagnosis of peripheral lung cancer: systematic review and meta-analysis. Eur Respir J 2011; 37: 902-910
• 16 Eberhardt R, Ernst A, Herth FJF. Ultrasound-guided transbronchial biopsy of solitary pulmonary nodules less than 20 mm. Eur Respir J 2009; 34: 1284-1287
• 17 Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003; 3: 733-744
• 18 Dietrich D, Hasinger O, Liebenberg V et al. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients. Diagnostic molecular pathology: the American journal of surgical pathology, part B 2012; 21: 93-104
• 19 Darwiche K, Zarogoulidis P, Baehner K et al. Assessment of SHOX2 methylation in EBUS-TBNA specimen improves accuracy in lung cancer staging. Ann Oncol 2013; 24: 2866-2870
• 20 Vannini I, Fanini F, Fabbri M. MicroRNAs as lung cancer biomarkers and key players in lung carcinogenesis. Clinical Biochemistry. The Canadian Society of Clinical Chemists 2013; 46: 918-925
• 21 Zhang N, Wei X, Xu L. miR-150 promotes the proliferation of lung cancer cells by targeting P53. FEBS Letters. Federation of European Biochemical Societies 2013; 587: 2346-2351
• 22 Lebanony D, Benjamin H, Gilad S et al. Diagnostic Assay Based on hsa-miR-205 Expression Distinguishes Squamous From Nonsquamous Non-Small-Cell Lung Carcinoma. Journal of Clinical Oncology 2009; 27: 2030-2037
• 23 Garofalo M, Romano G, Di Leva G et al. EGFR and MET receptor tyrosine kinase–altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 2011; 18: 74-82
• 24 Yu H, Jiang L, Sun C et al. Decreased circulating miR-375: A potential biomarker for patients with non-small-cell lung cancer. Gene. Elsevier B.V 2014; 534: 60-65
• 25 Boeri M, Verri C, Conte D et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A 108: 3713-3718
• 26 Plönes T, Elze M, Kayser G et al. mRNA and miRNA analyses in cytologically positive endobronchial ultrasound-guided transbronchial needle aspiration: Implications for molecular staging in lung cancer patients. Cancer Cytopathol 2014; 122: 292-298 [Epub 2014 Feb 26]
• 27 Tufman A, Huber RA. Biological markers in lung cancer: A clinician’s perspective 2009/2010. Cancer Biomarkers 6: 123-135
• 28 Cedrés S, Nuñez I, Longo M et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non–small-cell lung cancer (NSCLC). Clinical Lung Cancer 2011; 12: 172-179
• 29 Holdenrieder S, von Pawel J, Dankelmann E et al. Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer 2009; 63: 128-135
• 30 Tomita M, Shimizu T, Ayabe T et al. Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer. Anticancer Res 2010; 30: 3099-3102
• 31 Muley T, Fetz TH, Dienemann H et al. Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC. Lung Cancer 2008; 60: 408-415
• 32 Blankenburg F, Hatz R, Nagel D et al. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score. Tumour Biol 2008; 29: 272-277
• 33 Kozu Y, Maniwa T, Takahashi S et al. Prognostic significance of postoperative serum carcinoembryonic antigen levels in patients with completely resected pathological-stage I non-small cell lung cancer. J Cardiothorac Surg 2013; 8: 106
• 34 Colt HG, Murgu SD, Korst RJ et al. Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143: e437S-454S
• 35 Oberg K, Hellman P, Kwekkeboom D et al. Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21: v220-v222
• 36 Kneip C, Schmidt B, Seegebarth A et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J Thorac Oncol 2011; 6: 1632-1638
• 37 Mozzoni P, Banda I, Goldoni M et al. Plasma and EBC microRNAs as early biomarkers of non-small-cell lung cancer. Biomarkers 2013; 18: 679-686
• 38 McCulloch M, Jezierski T, Broffman M et al. Diagnostic accuracy of canine scent detection in early- and late-stage lung and breast cancers. Integr Cancer Ther 2006; 5: 30-39
• 39 Phillips M. Method for the collection and assay of volatile organic compounds in breath. Anal Biochem 1997; 247: 272-278
• 40 Dent AG, Sutedia TG, Zimmerman PV. Exhaled breath analysis for lung cancer. J Thorac Dis 2013; 5: 540-550
• 41 Wang Y, Hu Y, Wang D et al. The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines. Cancer Biomark 2012; 11: 129-137
• 42 Fu XA, Li M, Knipp RJ et al. Noninvasive detection of lung cancer using exhaled breath. Cancer Med 2013; [Epub ahead of print]
• 43 Darwiche K, Baumbach JI, Sommerwerck U et al. Bronchoscopically Obtained Volatile Biomarkers in Lung Cancer. Lung 2011; 189: 445-452
• 44 Peters S, Adjei AA, Gridelli C et al. ESMO Guidelines Working Group: Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; vii56-64
• 45 Lindeman NI, Cagle PT, Beasley MB et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 15: 415-453
• 46 Hirsch FR, Jänne PA, Eberhardt WE et al. Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol 2013; 373-384
• 47 Ying Wang, Wenlong Bao, Hua Shi et al. Epidermal Growth Factor Receptor Exon 20 Mutation Increased in Post-Chemotherapy Patients with Non-Small Cell Lung Cancer Detected with Patientsʼ Blood Samples. Transl Oncol 2013; 6: 504-510
• 48 Roberts PJ, Stinchcombe TE, Der CJ et al. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?. J Clin Oncol 2010; 28: 4769-4777
• 49 Hirsch FR, Jänne PA, Eberhardt WE et al. Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol 2013; 8: 373-384
• 50 Sholl LM, Weremowicz S, Gray SW et al. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol 2013; 8: 322-328
• 51 Liu Y, Yin TJ, Zhou R et al. Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis. Cancer Chemother Pharmacol 2013; 72: 1125-1132
• 52 Nicolson MC, Fennell DA, Ferry D et al. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J Thorac Oncol 2013; 8: 930-939
• 53 Hubner RA, Riley RD, Billingham LJ et al. Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. PLoS One 2011; 6: 25164
• 54 Gong W, Zhang X, Wu J et al. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Lung Cancer 2012; 75: 374-380
• 55 Bepler G, Williams C, Schell MJ et al. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2013; 31: 2404-2412